This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Csiki, I. Articles by Johnson, D. H. Search for Related Content PubMed PubMed Citation Articles by Csiki, I. Articles by Johnson, D. H.

Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel

Authors' Affiliations: Departments of ¹ Cancer Biology, ² Medicine (Hematology-Oncology and Clinical Pharmacology), and ³ Biostatistics, and ⁴ the Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

Requests for reprints: David H. Johnson, Vanderbilt-Ingram Cancer Center, 777 Preston Research Building, Nashville, TN 37232-6307. Phone: 615-343-9454; Fax: 615-936-2236; E-mail: david.johnson{at}vanderbilt.edu.

Cyclooxygenase-2 (COX-2) catalyzes the rate-limiting step in prostaglandin (PG) synthesis and is overexpressed in 70% to 90% of non–small cell lung cancers (NSCLC). Preclinical studies suggest inhibition of COX-2 can enhance the cytotoxic effect of docetaxel. To test this concept clinically, we administered celecoxib (400 mg p.o. twice daily) plus docetaxel (75 mg/m² every 3 weeks) to a cohort of patients with recurrent, previously treated NSCLC. Patients first received single agent celecoxib for 5 to 10 days to ascertain the effectiveness of COX-2 inhibition, which was determined by measuring pre- and post-celecoxib levels of urinary 11-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (PGE-M), the major metabolite of prostaglandin E₂ (PGE₂). We enrolled 56 patients (35 men, 21 women; median age, 61 years). All patients had received at least one prior chemotherapy regimen. The overall response rate was 11% and median survival was 6 months, similar to that observed with docetaxel alone. Pre-celecoxib urinary PGE-M decreased from a mean level of 27.2 to 12.2 ng/mg Cr after 5 to 10 days of celecoxib (P = 0.001). When grouped by quartile, patients with the greatest proportional decline in urinary PGE-M levels experienced a longer survival compared to those with no change or an increase in PGE-M (14.8 versus 6.3 versus 5.0 months). Our data suggest that combining celecoxib with docetaxel using the doses and schedule employed does not improve survival in unselected patients with recurrent, previously treated NSCLC. However, in light of the apparent survival prolongation in the subset with a marked decline in urinary PGE-M levels, further investigation of strategies designed to decrease PGE₂ synthesis in NSCLC seems warranted.

This article has been cited by other articles:

				R. Mutter, B. Lu, D. P. Carbone, I. Csiki, L. Moretti, D. H. Johnson, J. D. Morrow, A. B. Sandler, Y. Shyr, F. Ye, et al. A Phase II Study of Celecoxib in Combination with Paclitaxel, Carboplatin, and Radiotherapy for Patients with Inoperable Stage IIIA/B Non-Small Cell Lung Cancer Clin. Cancer Res., March 15, 2009; 15(6): 2158 - 2165. [Abstract] [Full Text] [PDF]

				E. Szabo Assessing Efficacy in Early-Phase Cancer Prevention Trials: The Case of Oral Premalignancy Cancer Prevention Research, October 1, 2008; 1(5): 312 - 315. [Full Text] [PDF]

				F. Di Cello, J. Hillion, J. Kowalski, B. M. Ronnett, A. Aderinto, D. L. Huso, and L. M.S. Resar Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts Mol. Cancer Ther., July 1, 2008; 7(7): 2090 - 2095. [Abstract] [Full Text] [PDF]

				M. J. Fidler, A. Argiris, J. D. Patel, D. H. Johnson, A. Sandler, V. M. Villaflor, J. Coon IV, L. Buckingham, K. Kaiser, S. Basu, et al. The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non-Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib Clin. Cancer Res., April 1, 2008; 14(7): 2088 - 2094. [Abstract] [Full Text] [PDF]

				M. G. Backlund, J. M. Amann, and D. H. Johnson Novel Strategies for the Treatment of Lung Cancer: Modulation of Eicosanoids J. Clin. Oncol., February 20, 2008; 26(6): 825 - 827. [Full Text] [PDF]

				M. J. Edelman, D. Watson, X. Wang, C. Morrison, R. A. Kratzke, S. Jewell, L. Hodgson, A. M. Mauer, A. Gajra, G. A. Masters, et al. Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy--Cancer and Leukemia Group B Trial 30203 J. Clin. Oncol., February 20, 2008; 26(6): 848 - 855. [Abstract] [Full Text] [PDF]

				I. Csiki and D. H. Johnson Did Targeted Therapy Fail Cyclooxygenase Too? J. Clin. Oncol., October 20, 2006; 24(30): 4798 - 4800. [Full Text] [PDF]

				L. Yang, Y. Huang, R. Porta, K. Yanagisawa, A. Gonzalez, E. Segi, D. H. Johnson, S. Narumiya, and D. P. Carbone Host and Direct Antitumor Effects and Profound Reduction in Tumor Metastasis with Selective EP4 Receptor Antagonism Cancer Res., October 1, 2006; 66(19): 9665 - 9672. [Abstract] [Full Text] [PDF]

				K. L. Reckamp, K. Krysan, J. D. Morrow, G. L. Milne, R. A. Newman, C. Tucker, R. M. Elashoff, S. M. Dubinett, and R. A. Figlin A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin. Cancer Res., June 1, 2006; 12(11): 3381 - 3388. [Abstract] [Full Text] [PDF]